• Lang Liu, Changwei Zhao, Shuang Zhao, Hanxun Xu, Zeyu Peng, Binghua Zhang, Wenjun Cai, Yifang Mo, and Wenhai Zhao.
• Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, China.
• Medicine (Baltimore). 2021 Dec 17; 100 (50): e28277e28277.

BackgroundKnee osteoarthritis (KOA) is a chronic degenerative disease involving cartilage and surrounding tissues. It causes a huge burden to social and medical resources and seriously affects people's living and working ability. In recent years, people have become increasingly interested in the application of Chinese medicine monomers to treat KOA. Among them, icariin plays an important role in the clinical treatment of KOA. Therefore, to evaluate the effectiveness and safety of icariin in the treatment of KOA, we conducted this study to provide a new basis for the clinical treatment of KOA.MethodsWe propose a systematic search of the PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and China Biomedical databases for all randomized controlled trials examining the use of icariin in the treatment of KOA patients up to October 20, 2021. The screening and data extraction processes will be performed independently by 2 researchers. We will use the Cochrane risk bias assessment tool to evaluate the quality of the studies that met the inclusion criteria. The data will be statistically analyzed using RevMan5.3 software.ResultThis study will provide high-quality evidence for the effectiveness and safety of icariin in the treatment of KOA.ConclusionThe purpose of this study was to explore the efficacy of icariin in the treatment of KOA and to provide clinicians and patients with new treatment strategies.Inplasy Registration NumberINPLASY2021110015.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

23 keywords...

hide…